Dominion Energy (NYSE:D) Updates FY25 Earnings Guidance
by Scott Moore · The Cerbat GemDominion Energy (NYSE:D – Get Free Report) issued an update on its FY25 earnings guidance on Friday morning. The company provided EPS guidance of $3.25-3.54 for the period, compared to the consensus EPS estimate of $3.38. Dominion Energy also updated its FY 2024 guidance to 2.680-2.830 EPS.
Analyst Ratings Changes
A number of equities research analysts recently commented on D shares. Barclays upped their target price on Dominion Energy from $54.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, October 15th. Scotiabank increased their price objective on shares of Dominion Energy from $48.00 to $58.00 and gave the stock a “sector perform” rating in a research note on Tuesday, August 20th. Jefferies Financial Group began coverage on shares of Dominion Energy in a report on Friday, September 20th. They set a “hold” rating and a $58.00 target price for the company. JPMorgan Chase & Co. increased their price target on Dominion Energy from $54.00 to $57.00 and gave the stock a “neutral” rating in a research report on Monday, August 12th. Finally, BMO Capital Markets lifted their price objective on Dominion Energy from $53.00 to $57.00 and gave the company a “market perform” rating in a research note on Monday, August 5th. Nine equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Dominion Energy currently has a consensus rating of “Hold” and a consensus target price of $55.40.
View Our Latest Stock Analysis on D
Dominion Energy Price Performance
Shares of NYSE:D traded down $1.22 during trading on Monday, reaching $57.77. 2,533,968 shares of the company’s stock traded hands, compared to its average volume of 4,390,817. The company has a quick ratio of 0.78, a current ratio of 0.93 and a debt-to-equity ratio of 1.42. Dominion Energy has a fifty-two week low of $43.53 and a fifty-two week high of $61.97. The company has a 50-day simple moving average of $57.87 and a 200-day simple moving average of $54.14. The firm has a market cap of $48.47 billion, a PE ratio of 31.05, a P/E/G ratio of 1.58 and a beta of 0.59.
Dominion Energy (NYSE:D – Get Free Report) last issued its quarterly earnings data on Friday, November 1st. The utilities provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.92 by $0.06. The company had revenue of $3.94 billion for the quarter, compared to analyst estimates of $4.18 billion. Dominion Energy had a return on equity of 7.69% and a net margin of 11.63%. Dominion Energy’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period last year, the company earned $0.77 earnings per share. As a group, analysts predict that Dominion Energy will post 2.76 earnings per share for the current year.
Dominion Energy Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 20th. Shareholders of record on Friday, November 29th will be issued a dividend of $0.6675 per share. This represents a $2.67 annualized dividend and a yield of 4.62%. The ex-dividend date of this dividend is Friday, November 29th. Dominion Energy’s payout ratio is 140.53%.
Dominion Energy Company Profile
Dominion Energy, Inc produces and distributes energy in the United States. It operates through three operating segments: Dominion Energy Virginia, Dominion Energy South Carolina, and Contracted Energy. The Dominion Energy Virginia segment generates, transmits, and distributes regulated electricity to approximately 2.8 million residential, commercial, industrial, and governmental customers in Virginia and North Carolina.
Read More
- Five stocks we like better than Dominion Energy
- Golden Cross Stocks: Pattern, Examples and Charts
- Intel: Is Now the Time to Be Brave?
- Stock Sentiment Analysis: How it Works
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- 3 Tickers Leading a Meme Stock Revival
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?